EGFR and non-small cell lung carcinoma: Furthermore, pembrolizumab was found to provide limited effect in EGFR-mutant advanced NSCLC population who never received TKI treatment, even among those with PD-L1 expression more than 50%, indicating ICI monotherapy was not a suitable therapeutic choice for this group of patients [179].